Los Angeles Capital Management’s Oric Pharmaceuticals ORIC Stock Holding History

Los Angeles Capital Management’s Portfolio ORIC Stock Details ORIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-43,137	Closed	-$547K	–	2460
2026 Q1	$547K	Buy	+43,137	New	+$490K	﹤0.01%	846
2022 Q2	–	Sell	-35,830	Closed	-$191K	–	1421
2022 Q1	$191K	Buy	35,830 +15,450	+76%	+$139K	﹤0.01%	1364
2021 Q4	$300K	Hold	20,380	–	–	﹤0.01%	1238
2021 Q3	$426K	Sell	20,380 -1,520	-7%	-$30.8K	﹤0.01%	1131
2021 Q2	$387K	Buy	+21,900	New	+$480K	﹤0.01%	1286

Other funds holding ORIC

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Los Angeles Capital Management's ORIC Position: Q2 2026 in Review

Los Angeles Capital Management sold out of Oric Pharmaceuticals (ORIC) in Q2 2026, closing a stake of 43,137 shares — an estimated $547K sold.

Los Angeles Capital Management first reported a position in ORIC in Q2 2021 and held it in 5 quarters. The position peaked at $547K in Q1 2026. 180 funds tracked by Wall St. Rank hold ORIC as of Q2 2026.

Los Angeles Capital Management reported no remaining Oric Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Los Angeles Capital Management sold 43,137 Oric Pharmaceuticals shares in Q2 2026, an estimated $547K.
Los Angeles Capital Management first reported a position in Oric Pharmaceuticals in Q2 2021 and held it in 5 quarters.
Los Angeles Capital Management's Oric Pharmaceuticals position peaked at $547K in Q1 2026.
180 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2026.

Based on Los Angeles Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.